Sterling Capital Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

Sterling Capital Management’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.11K	Sell	419 -2,499	-86%	-$39.9K	﹤0.01%	2417
2026 Q1	$43.2K	Sell	2,918 -1,236	-30%	-$18.1K	﹤0.01%	1704
2025 Q4	$66.3K	Buy	4,154 +3,872	+1,373%	+$54.9K	﹤0.01%	1694
2025 Q3	$3.12K	Sell	282 -3	-1%	-$33	﹤0.01%	2905
2025 Q2	$2.41K	Sell	285 -433	-60%	-$3.47K	﹤0.01%	2873
2025 Q1	$5.77K	Sell	718 -531	-43%	-$4.3K	﹤0.01%	2091
2024 Q4	$11.2K	Buy	1,249 +1,030	+470%	+$8.4K	﹤0.01%	2110
2024 Q3	$1.6K	Buy	+219	New	+$1.36K	﹤0.01%	2296

Other funds holding AUPH

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sterling Capital Management's AUPH Position: Q2 2026 in Review

Sterling Capital Management reduced its Aurinia Pharmaceuticals (AUPH) stake by 86% in Q2 2026, selling an estimated $39.9K and leaving 419 shares worth $7.11K. The position accounts for ﹤0.01% of the portfolio, ranked #2417.

Sterling Capital Management first reported a position in AUPH in Q3 2024 and has held it in 8 quarters since. The position peaked at $66.3K in Q4 2025. 283 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

Sterling Capital Management held 419 shares of Aurinia Pharmaceuticals worth $7.11K as of Q2 2026.
Sterling Capital Management sold 2,499 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $39.9K.
Aurinia Pharmaceuticals made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2417 holding.
Sterling Capital Management first reported a position in Aurinia Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
Sterling Capital Management's Aurinia Pharmaceuticals position peaked at $66.3K in Q4 2025.
283 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.